Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Jasmycoin (JASMY) Dips To Test Key Support – Could This Pattern Trigger a Bounce Back?

Jasmycoin (JASMY) Dips To Test Key Support – Could This Pattern Trigger a Bounce Back?

CoinsProbeCoinsProbe2025/09/25 17:21
By:Nilesh Hembade

Date: Wed, Sept 24, 2025 | 11:10 AM GMT

The cryptocurrency market is seeing heightened volatility after the Fed-driven surge, with Bitcoin (BTC) and Ethereum (ETH) both sliding into weekly losses. Unsurprisingly, altcoins are also under pressure, including Jasmycoin (JASMY).

Over the past week, JASMY has dropped more than 9%. More importantly, the coin is now testing a crucial technical level that could determine whether it rebounds or breaks down further.

Jasmycoin (JASMY) Dips To Test Key Support – Could This Pattern Trigger a Bounce Back? image 0 Source: Coinmarketcap

Symmetrical Triangle in Play

On the daily chart, JASMY has been consolidating inside a symmetrical triangle — a neutral pattern that usually precedes a decisive breakout in either direction.

Currently, the correction has dragged JASMY toward the triangle’s lower boundary near $0.012, where buyers are showing signs of defense. At the time of writing, the token is trading around $0.01286, sitting directly on a key technical support zone.

Jasmycoin (JASMY) Dips To Test Key Support – Could This Pattern Trigger a Bounce Back? image 1 Jasmycoin (JASMY) Daily Chart/Coinsprobe (Source: Tradingview)

This trendline has served as dynamic support for several months, making it a critical battleground for bulls. Holding above this level could signal strength and set the stage for a rebound.

What’s Next for JASMY?

If bulls manage to defend the $0.012 support, JASMY could rebound toward the upper resistance of the triangle, around $0.0173. A breakout above this zone would confirm bullish continuation, potentially sparking momentum for a larger rally.

On the flip side, if JASMY slips below $0.012, it would confirm a bearish breakdown, opening the door to deeper losses and possibly triggering panic-driven selling.

The next move in JASMY hinges on how it reacts at this support zone. A strong defense could invite a relief rally, while failure to hold may lead to further downside.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23

Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market

Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.

智通财经•2026/11/06 12:37
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market